Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQJXL4)

Drug Name
AMG 386 Drug Info
Synonyms
7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [1]
Neuropathic pain 8E43.0 Phase 3 [2]
Alzheimer disease 8A20 Phase 2 [3]
Asthma CA23 Discontinued in Phase 2 [4]
Sexual dysfunction HA00-HA01 Preclinical [5]
Cross-matching ID
PubChem CID
5360545
ChEBI ID
CHEMBL26708
CAS Number
CAS 7440-23-5
TTD Drug ID
DMQJXL4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Angiopoietin-2 (ANGPT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Faricimab DM83SEB Diabetic macular edema 9B71.02 Approved [19]
Trebananib DMOG2X1 Ovarian cancer 2C73 Phase 3 [20]
RG7221 DM8J9DC Colorectal cancer 2B91.Z Phase 2 [21]
RO5520985 DMD3WNP Colorectal cancer 2B91.Z Phase 2 [22]
LY3127804 DMAC457 Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 Trial [23]
REGN910-3 DMTBRPO Neovascular age-related macular degeneration 9B78.3Z Phase 2 [24]
CVX-060 DM03LWZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [25]
BI 836880 DMRI6YT Neoplasm 2A00-2F9Z Phase 1 [26]
CVX-241 DMV74JC Solid tumour/cancer 2A00-2F9Z Phase 1 [27]
REGN-910 DMHR7D4 Solid tumour/cancer 2A00-2F9Z Phase 1 [28]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor (OPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methadone DMTW6IU Advanced cancer 2A00-2F9Z Approved [29]
Ketobemidone DMM3L6Z Pain MG30-MG3Z Approved [30]
Oxymorphone DM65AGJ Pain MG30-MG3Z Approved [31]
Dextropropoxyphene DM23HCX Pain MG30-MG3Z Approved [32]
Sufentanil DMU7YEL Analgesia MB40.8 Approved [33]
Naltrexone DMUL45H Alcohol dependence 6C40.2 Approved [34]
Levorphanol DMGS80V Pain MG30-MG3Z Approved [35]
Pentazocine DM1XBHS Pain MG30-MG3Z Approved [36]
Nalmefene DM4YWCZ Opioid dependence 6C43.2Z Approved [37]
Tilidine DMJW0VS Pain MG30-MG3Z Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Neuronal acetylcholine receptor alpha-7 (CHRNA7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ziprasidone DMM58JY Bipolar disorder 6A60 Approved [39]
ALCURONIUM DM2U4XQ Anaesthesia 9A78.6 Approved [40]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [41]
EVP-6124 DMLQO7F Alzheimer disease 8A20 Phase 3 [42]
GTS-21 DMEN5KA Parkinson disease 8A00.0 Phase 2 [43]
JNJ-39393406 DMUOEKM Depression 6A70-6A7Z Phase 2 [44]
ABT-126 DM2OS51 Alzheimer disease 8A20 Phase 2 [45]
TC-6987 DMNFP21 Asthma CA23 Phase 2 [46]
AQW-051 DMD2RFO Alzheimer disease 8A20 Phase 2 [47]
MEM-3454 DMPNDYU Schizophrenia 6A20 Phase 2 [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Angiopoietin-1 (ANGPT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trebananib DMOG2X1 Ovarian cancer 2C73 Phase 3 [20]
AMG 780 DMTGZN8 Solid tumour/cancer 2A00-2F9Z Phase 1 [48]
Drug(s) Targeting TAX transcriptionally-activated glycoprotein 1 (OX40)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7888 DM2SWI8 Solid tumour/cancer 2A00-2F9Z Phase 2 [49]
Amlitelimab DMKR3BQ Asthma CA23 Phase 2 [50]
mRNA-2752 DMUKBI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [51]
MEDI6383 DM1YSMD Solid tumour/cancer 2A00-2F9Z Phase 1 [52]
mRNA-2416 DMFTAWU Lymphoma 2A80-2A86 Phase 1 [53]
SAR442970 DM3DHWE Inflammation 1A00-CA43.1 Phase 1 [54]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Melanocortin receptor 4 (MC4R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylnaltrexone bromide DMZTGN2 Opioid-induced constipation DB32.1 Approved [5]
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [55]
Setmelanotide DMPVRN9 Obesity 5B81 Approved [56]
Amylin DMWDEN0 N. A. N. A. Phase 4 [57]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [58]
PF-446687 DML38VU Female sexual arousal dysfunction HA01.1 Phase 2 [59]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [6]
PF-07258669 DM3CJ5N Malnutrition 5B50-5B71 Phase 1 [60]
PT-14 DMYM9JL Erectile dysfunction HA01.1 Discontinued in Phase 2 [61]
Melanotetan II DMYK8MV Obesity 5B81 Preclinical [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Gamma-secretase (GS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [62]
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [63]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [64]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [63]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [65]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [66]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [67]
RO-4929097 DMXA6B3 Breast cancer 2C60-2C65 Phase 2 [68]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [69]
SPI-014 DM5IPUS Alzheimer disease 8A20 Phase 1 [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Ceruloplasmin (CP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [71]
Quercetin DM3NC4M Obesity 5B81 Approved [72]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [73]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [74]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [75]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [76]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [77]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [78]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [79]
Ampicillin DMHWE7P Acute epiglottitis Approved [72]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [80]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [81]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [82]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [83]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [84]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [85]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [86]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [87]
Epinephrine DM3KJBC Acute asthma CA23 Approved [88]
Chlorthalidone DM4DMBT Edema MG29 Approved [89]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Kallikrein-1 (KLK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [90]
Magnesium DMU4ORS Ischemic stroke 8B11.5Z Approved [11]
Dobutamine DMD1B8Z Heart failure BD10-BD13 Approved [91]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [92]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [93]
acetaldehyde DMJFKG4 Discovery agent N.A. Investigative [94]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Affected By Band 3 anion transport protein (SLC4A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [95]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [96]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [97]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [98]
Adefovir DMM278X N. A. N. A. Approved [99]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [100]
CHLORIDE DM1TJXA Solid tumour/cancer 2A00-2F9Z Phase 3 [101]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [93]
D-glucose DMMG2TO Discovery agent N.A. Investigative [102]
Selenious acid DMB7GPA N. A. N. A. Investigative [103]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium/nucleoside cotransporter 2 (SLC28A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Uridine DMQTREB Depression 6A70-6A7Z Approved [15]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [104]
Arsenic DMTL2Y1 N. A. N. A. Approved [105]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [106]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [107]
Adenosine DMM2NSK Paroxysmal supraventricular tachycardia BC81.Z Approved [15]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [108]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [109]
Purine Riboside DMHNS0V Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [110]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [96]
Menthol DMG2KW7 Back pain ME84.Z Approved [111]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [112]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [108]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [93]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [113]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [114]
Selenium DM25CGV N. A. N. A. Approved [115]
Methotrexate DM2TEOL Anterior urethra cancer Approved [116]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [117]
Epinephrine DM3KJBC Acute asthma CA23 Approved [118]
Quercetin DM3NC4M Obesity 5B81 Approved [119]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [120]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [121]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [122]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [123]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transient receptor potential cation channel subfamily V member 4 (TRPV4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [124]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [125]
Leflunomide DMR8ONJ Arthritis FA20 Approved [126]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [127]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [128]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [93]
Arachidonic Acid DMUOQZD Discovery agent N.A. Investigative [129]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Affected By Secretin (SCT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [130]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [131]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [96]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [97]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [132]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [128]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [133]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [134]
Pentagastrin DMRCLZB Diagnostic imaging N.A. Approved [135]
CHLORIDE DM1TJXA Solid tumour/cancer 2A00-2F9Z Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium/hydrogen exchanger 7 (SLC9A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [125]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [136]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [14]
Arsenic DMTL2Y1 N. A. N. A. Approved [105]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [128]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [93]
PMID28870136-Compound-52 DMFDERP N. A. N. A. Patented [137]
Milchsaure DM462BT Pruritus EC90 Investigative [138]
benzamil DM57SVW Discovery agent N.A. Investigative [14]
3-iodothyronamine DM3L0F8 Discovery agent N.A. Investigative [139]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin-1 (ANGPT1) TTWNQ1T ANGP1_HUMAN Modulator [6]
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Modulator [6]
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Inhibitor [7]
Melanocortin receptor 4 (MC4R) TTD0CIQ MC4R_HUMAN Agonist [5]
Neuronal acetylcholine receptor alpha-7 (CHRNA7) TTLA931 ACHA7_HUMAN Agonist [7]
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Agonist [2]
TAX transcriptionally-activated glycoprotein 1 (OX40) TTBW580 TNFL4_HUMAN Modulator [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Band 3 anion transport protein (SLC4A1) OT3EFUK8 B3AT_HUMAN Regulation of Drug Effects [9]
Ceruloplasmin (CP) OTM8JE4Y CERU_HUMAN Protein Interaction/Cellular Processes [10]
Kallikrein-1 (KLK1) OTFGP3UR KLK1_HUMAN Gene/Protein Processing [11]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [12]
Secretin (SCT) OTV3MLOO SECR_HUMAN Regulation of Drug Effects [13]
Sodium/hydrogen exchanger 7 (SLC9A7) OTVDLTYA SL9A7_HUMAN Regulation of Drug Effects [14]
Sodium/nucleoside cotransporter 2 (SLC28A2) OTFYZK8R S28A2_HUMAN Regulation of Drug Effects [15]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Regulation of Drug Effects [16]
Transient receptor potential cation channel subfamily V member 4 (TRPV4) OTPZKQLX TRPV4_HUMAN Regulation of Drug Effects [17]
Voltage-dependent R-type calcium channel subunit alpha-1E (CACNA1E) OTHATMLU CAC1E_HUMAN Regulation of Drug Effects [18]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8414).
2 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
3 Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009 Sep;8(9):733-50.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027884)
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Clinical pipeline report, company report or official report of Roche (2009).
8 Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
9 Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1. Nat Genet. 2005 Nov;37(11):1258-63. doi: 10.1038/ng1656. Epub 2005 Oct 9.
10 Ceruloplasmin revisited: structural and functional roles of various metal cation-binding sites. Acta Crystallogr D Biol Crystallogr. 2007 Feb;63(Pt 2):240-8. doi: 10.1107/S090744490604947X. Epub 2007 Jan 16.
11 The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. J Enzyme Inhib Med Chem. 2004 Aug;19(4):317-25. doi: 10.1080/14756360409162444.
12 Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. Am J Physiol Heart Circ Physiol. 2001 May;280(5):H2248-54. doi: 10.1152/ajpheart.2001.280.5.H2248.
13 The influence of secretin on ion transport in the human jejunum. Gut. 1973 Jun;14(6):485-90. doi: 10.1136/gut.14.6.485.
14 Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. J Biol Chem. 2001 May 18;276(20):17387-94. doi: 10.1074/jbc.M101319200. Epub 2001 Feb 26.
15 Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol. 1998 Oct-Dec;15(4):203-11. doi: 10.3109/09687689709044322.
16 Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. Transplant Proc. 2009 Nov;41(9):3603-10. doi: 10.1016/j.transproceed.2009.04.008.
17 A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14034-9. doi: 10.1073/pnas.0904084106. Epub 2009 Aug 4.
18 Inactivation properties of human recombinant class E calcium channels. J Neurophysiol. 2000 Feb;83(2):671-84. doi: 10.1152/jn.2000.83.2.671.
19 Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
20 Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
21 Company report (Roche pipeline: July 27, 2017)
22 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
24 ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
25 Clinical pipeline report, company report or official report of CovX (2011).
26 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
27 Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
28 Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18.
29 Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
30 The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
32 Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
33 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
34 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
35 Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
36 Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
37 Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
38 Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
39 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
40 Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
41 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
42 Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
43 The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
44 Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
45 A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
46 ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
47 AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
48 Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.
49 Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
50 OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
51 Clinical pipeline report, company report or official report of Moderna Therapeutics.
52 J Clin Oncol 33, 2015 (suppl; abstr 3056).
53 Clinical pipeline report, company report or official report of Moderna Therapeutics.
54 Clinical pipeline report, company report or official report of Sanofi
55 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
56 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
57 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
58 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
59 Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
60 Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
61 The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
62 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
63 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
64 A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
65 Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
66 Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
67 CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
68 Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
69 Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
70 Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.
71 Reactive oxygen species regulate ceruloplasmin by a novel mRNA decay mechanism involving its 3'-untranslated region: implications in neurodegenerative diseases. J Biol Chem. 2009 Jan 16;284(3):1873-83. doi: 10.1074/jbc.M804079200. Epub 2008 Nov 18.
72 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
73 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
74 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
75 DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
76 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
77 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
78 In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol. 2016 Mar;90(3):677-89. doi: 10.1007/s00204-015-1483-z. Epub 2015 Feb 26.
79 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
80 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
81 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
82 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
83 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
84 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
85 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
86 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
87 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
88 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
89 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
90 Experimental studies on cortisol-induced hypertension in humans. J Hum Hypertens. 1995 Jun;9(6):395-9.
91 Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension. 2002 Nov;40(5):653-9. doi: 10.1161/01.hyp.0000036035.41122.99.
92 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
93 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
94 Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
95 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
96 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
97 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
98 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
99 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
100 Resveratrol induces human K562 cell apoptosis, erythroid differentiation, and autophagy. Tumour Biol. 2014 Jun;35(6):5381-8. doi: 10.1007/s13277-014-1701-y. Epub 2014 Feb 15.
101 Lysine 539 of human band 3 is not essential for ion transport or inhibition by stilbene disulfonates. J Biol Chem. 1989 Nov 25;264(33):19607-13.
102 Novel oxolane derivative DMTD mitigates high glucose-induced erythrocyte apoptosis by regulating oxidative stress. Toxicol Appl Pharmacol. 2017 Nov 1;334:167-179.
103 Human red blood cell uptake and sequestration of arsenite and selenite: Evidence of seleno-bis(S-glutathionyl) arsinium ion formation in human cells. Biochem Pharmacol. 2020 Oct;180:114141. doi: 10.1016/j.bcp.2020.114141. Epub 2020 Jul 8.
104 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
105 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
106 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
107 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
108 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
109 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
110 Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
111 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
112 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
113 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
114 Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
115 Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
116 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
117 P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
118 Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
119 Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
120 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
121 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
122 Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
123 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
124 Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4. Autophagy. 2021 Nov;17(11):3592-3606. doi: 10.1080/15548627.2021.1885203. Epub 2021 Feb 25.
125 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
126 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
127 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
128 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
129 Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9.
130 Retinoic acid-induced human secretin gene expression in neuronal cells is mediated by cyclin-dependent kinase 1. Ann N Y Acad Sci. 2006 Jul;1070:393-8. doi: 10.1196/annals.1317.051.
131 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
132 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
133 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
134 Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006 Mar;28(2):99-103. doi: 10.1016/j.braindev.2005.05.005. Epub 2005 Sep 15.
135 Secretin inhibits canine gastric acid secretion in response to pentagastrin by modulating gastric histamine release. J Pharmacol Exp Ther. 1996 Nov;279(2):718-23.
136 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
137 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
138 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
139 Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.